Premium
Terbinafine‐induced hepatic failure requiring liver transplantation
Author(s) -
Perveze Zeeshan,
Johnson Mark W.,
Rubin Raymond A.,
Sellers Marty,
Zayas Carlos,
Jones Jody L.,
Cross Rosemary,
Thomas Kimberly,
Butler Bradley,
Shrestha Roshan
Publication year - 2007
Publication title -
liver transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.814
H-Index - 150
eISSN - 1527-6473
pISSN - 1527-6465
DOI - 10.1002/lt.21034
Subject(s) - medicine , liver transplantation , fulminant hepatic failure , liver injury , acetaminophen , liver disease , chronic liver disease , liver failure , terbinafine , gastroenterology , transplantation , pharmacology , cirrhosis , antifungal , dermatology , itraconazole
Drug‐induced liver disease accounts for about 50% of acute or subacute liver failure in the United States. United Network of Organ Sharing (UNOS) data suggest 8%‐20% of liver transplantation in this country per year is for fulminant liver failure due to drugs. Even though the most common medication implicated in acute liver injury is acetaminophen (75%), there are numerous other drugs that are responsible for acute and chronic liver injury. A variety of antifungal medications are known to cause a wide range of liver injury from a mild hepatocellular‐cholestatic injury pattern to acute/subacute liver failure. Terbinafine is one of the antifungals that have been associated with such liver injuries. We report a case of terbinafine‐induced severe liver failure requiring liver transplantation. Liver Transpl 13:162–164, 2007. © 2006 AASLD.